Company intelligence / Profile preview

Youshan Biomedical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

The company's lead CAR-NK candidate, NRC-NK-01, demonstrated clinical safety and signs of efficacy in a Phase I pilot study for metastatic solid tumors (including colorectal cancer), showing rapid tumor regression and reduction in malignant ascites. The company also licensed SOM0777, an integrin antagonist, which is in Phase I development for glioblastoma.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-NK cell therapySmall moleculeOncolytic virus therapy
Industry: Biotech

Partnerships

SOM BiotechHangzhou Converd Co., Ltd.The Third Affiliated Hospital of Guangzhou Medical University

Beyond the preview

Go deeper on Youshan Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Youshan Biomedical.

Explore the full profile